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0022-2836 © 2010 Elsevier Ltd.Open acceThe mammalian SPRY domain- and SOCS box-containing proteins, SPSB1
to SPSB4, belong to the SOCS box family of E3 ubiquitin ligases. Substrate
recognition sites for the SPRY domain are identified only for human Par-4
(ELNNNL) and for the Drosophila orthologue GUSTAVUS binding to the
DEAD-box RNA helicase VASA (DINNNN). To further investigate this
consensus motif, we determined the crystal structures of SPSB1, SPSB2, and
SPSB4, as well as their binding modes and affinities for both Par-4 and
VASA. Mutation of each of the three Asn residues in Par-4 abrogated
binding to all three SPSB proteins, while changing EL to DI enhanced
binding. By comparison to SPSB1 and SPSB4, the more divergent protein
SPSB2 showed only weak binding to Par-4 and was hypersensitive to DI
substitution. Par-4(59–77) binding perturbed NMR resonances from a number
of SPSB2 residues flanking the ELNNN binding site, including loop D,
which binds the EL/DI sequence. Although interactions with the consensus
peptide motif were conserved in all structures, flanking sites in SPSB2 were
identified as sites of structural change. These structural changes limit high-
affinity interactions for SPSB2 to aspartate-containing sequences, whereas
SPSB1 and SPSB4 bind strongly to both Par-4 and VASA peptides.© 2010 Elsevier Ltd.Open access under CC BY license. Keywords: X-ray crystallography; NMR; ITC; protein structure; protein–
peptide interactionEdited by K. MorikawaIntroduction
The SPRY domain- and SOCS box-containing
proteins, SPSB1 to SPSB4 (also known as SSB-1 to
-4), contain a protein interaction domain known as
the SPRY domain, which was first identified as aresses:
sgc.ox.ac.uk.
y to this work.
onuclear single
main- and SOCS
an prostate apoptosis
PSB; ITC, isothermal
e SPSB; PDB, Protein
ferase; PEG,
ss under CC BY license. sequence repeat in the dual-specificity kinase splA
and ryanodine receptors,1 together with a C-terminal
SOCS box motif.2 The presence of the SOCS box
motif suggests that the SPSB proteins may
function as part of an E3 ubiquitin ligase, with the
SPRY domain determining the substrate(s) for
ubiquitination,3 and this has been confirmed recently
for SPSB2 (Z.K., R.S.L., R.S.N., and S.E.N.,
personal communication). All four SPSB proteins
also interact with c-Met, the hepatocyte growth
factor receptor,4 and SPSB1, SPSB2, and SPSB4, but
not SPSB3, interact with human prostate apoptosis
response protein-4 (hPar-4).5 hPar-4 is up-regulated
in prostate cancer cells undergoing apoptosis6 and
appears to be a regulator of the ζPKC–NF-κB
pathway, with Par-4 null mice showing enhanced
T-cell proliferation and tumor formation, primarily
through increased NF-κB signalling and resistance
to apoptosis.7,8 The Drosophila SPSB protein
Table 1. ITC analysis of hPar-4 peptide interactions with mSPSB proteins
Ligands Proteins Kd
a
hPar-4(59–77) GTPAAAAANELNNNLPGGA mSPSB2(12–224) 4.6±0.1 μM
mSPSB4ΔSB 189±1 nM
mSPSB2+elonginBC 4.3±0.6 μM
mSPSB4+elonginBC 214±36 nM
mSPSB2(12–224)[Y120A] nm
b
mSPSB2(12–224)[123–5] nm
mSPSB2(12–224)[126–8] nm
mSPSB2(12–224)[T198A] 3.0±0.2 μM
mSPSB2(12–224)[V206A] nm
[N72A]hPar-4(59–77) GTPAAAAANELNNALPGGA mSPSB2(12–224) nm
mSPSB4+elonginBC nm
hPar-4(64–77) AAANELNNNLPGGA mSPSB2(12–224) 3.2±0.002 μM
mSPSB4ΔSB 213±7 nM
mSPSB1ΔSB 210±19 nM
[N70A]hPar-4(64–77) AAANELANNLPGGA mSPSB2(12–224) nm
mSPSB4ΔSB nm
mSPSB1ΔSB nm
[N71A]hPar-4(64–77) AAANELNANLPGGA mSPSB2(12–224) nm
mSPSB4ΔSB nm
mSPSB1ΔSB nm
[E68D,L69I]hPar-4(64–77) AAANDINNNLPGGA mSPSB2(12–224) 106±30 nM
mSPSB4ΔSB 33±23 nM
mSPSB1ΔSB 40±5 nM
[E68D]hPar-4(64–77) AAANDLNNNLPGGA mSPSB2(12–224) 208±13 nM
mSPSB4ΔSB 47±22 nM
[L69I]hPar-4(64–77) AAANEINNNLPGGA mSPSB2(12–224) 1.6±0.4 μM
mSPSB4ΔSB 55±8 nM
[A66D]hPar-4(59–77) GTPAAAADNELNNNLPGGA mSPSB2(12–224) 4.0±0.9 μM
mSPSB4ΔSB 255±5 nM
a Kd value deviations are shown as the standard error of the mean.
b nm, not measurable because KdN50 μM.
390 Structural Basis for Par-4 Recognition by SPSBshomologue, GUSTAVUS, interacts with the DEAD-
box RNA helicase VASA.9 The identification of
similar sequences in hPar-4 (ELNNNL) and VASA
(DINNNN)10 suggests that the SPSB1, SPSB2, and
SPSB4 SPRY domains may recognize a common
peptide epitope in these proteins.
There are currently N1600 eukaryotic proteins
recognized as containing a SPRY domain in the
SMART database,11 with 46 encoded in the human
genome. More than half of the known SPRY
domains have a conserved N-terminal extension
(PRY domain), which, together with the SPRY
domain, creates the B30.2 domain.12,13 However, in
proteins such as SPSB2 that do not contain a PRY
domain, this motif is replaced by a similar structural
domain with no obvious sequence homology to the
PRY motif, even though such proteins are often
referred to simply as SPRY domains; thus, at the
structural level, PRYSPRY domains could be
regarded as a subset of SPRY domains,14 even
though current nomenclature would suggest the
converse. Three-dimensional structures of several
B30.2/SPRY domain-containing proteins have been
published recently.5,10,14,15–18 Structural compari-
sons also reveal similarity to two structures of
Neuralized homology repeat domains (also known
as NEUZ domains).14,19
The specific functions of B30.2/SPRY domain-
containing proteins encoded by the human genome
are poorly characterized, but our understanding is
expected to increase greatly with the identificationof their respective interaction partners. All reported
B30.2/SPRY domain structures have a broadly
similar β-sandwich core but show differences in
the surface-exposed regions, consistent with their
binding to diverse sets of ligands. The GUSTAVUS
complex with VASA maps the binding site to five
variable loops (designated A–E) on the opposite face
of the SPRY domain to the C-terminal SOCS box,
while the primary binding epitope of VASA is the
hexapeptide sequence DINNNN. In Drosophila, this
interaction is required for the localization of VASA
to the posterior pole of the developing oocyte, with
GUSTAVUS mutations causing female sterility.9
SPSB1 and SPSB4 are similarly proposed to regulate
germ cell physiology, showing expression in the
mouse ovary in granulosa cells at all stages of
follicular development.20 However, the VASA epi-
tope is absent in the human orthologue and other
ligands await identification. Importantly, GUSTA-
VUS and human SPSB1 (hSPSB1) are competent to
bind the similar ELNNNL sequence of hPar-4,
suggesting that the hSPSB family proteins will
share a conserved recognition mode in their
substrates.10
In this article, we investigate the potential
conservation of the peptide binding mode in the
murine and hSPSB family proteins. NMR spectros-
copy was employed to screen for additional
residues in hPar-4 that participate in SPSB binding,
and the contributions of key positions were
analyzed by mutagenesis and binding affinity
Fig. 1. Identification of key interacting residues of hPar-4. (a) Comparison of HSQC spectra of uniformly 15N-labeled
hPar-4(59–77), free (red) and in a 1:1 complex with mSPSB2(12–224) (blue). Spectra were recorded on 0.1-mM solutions in 95%
H2O/5%
2H2O, pH 6.7, and 295 K, using a Bruker Avance500 spectrometer with a cryoprobe. (b) Weighted average
chemical shift variations of 15N and 1H between free and bound forms of 15N-labeled hPar-4(59–77). The weighted averages
of the three Asn residues, Asn70–72 (blue asterisks and blue bars), are a representation only, as the peaks in the complex
may have shifted more than indicated. Green asterisks correspond to residues (Gly59, Pro61, and Pro74) not observed in
these spectra, while the purple asterisk denotes a very weak peak from Thr60.
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392 Structural Basis for Par-4 Recognition by SPSBsmeasurements. Crystal structures were then solved
for hSPSB1 in complex with hPar-4 and VASA, the
hSPSB2 complex with VASA, and apo-hSPSB4, inFig. 2 (legendorder to understand the significant differences in
their relative affinities and preferred peptide
sequences.on next page)
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Interaction of hPar-4 peptides with mSPSBs
via ITC
The interaction of Par-4 with SPSB family
members was investigated initially using murine
SPSB (mSPSB) proteins because of the availability of
mSPSB2 mutants5 and a set of NMR assignments.21
Isothermal titration calorimetry (ITC) measure-
ments showed that hPar-4(59–77) bound to
mSPSB2-elonginBC with low micromolar affinity
(Kd=4.3 μM) (Table 1) and to mSPSB4-elonginBC
more strongly (Kd=214 nM). It has been shown in
an affinity purification assay that the interactions of
hPar-4 with mSPSB1, mSPSB2, and mSPSB4 are
mediated via the SPRY domain.5 Our data con-
firmed that the absence of the SOCS box and
elonginBC did not affect binding affinities, with
mSPSB2ΔSB and mSPSB4ΔSB showing Kd values
with hPar4(59–77) of 4.6 μM and 189 nM, respectively
(Table 1).
mSPSB1 and mSPSB4 bound the shorter hPar-4
peptide, hPar-4(64–77), tightly, with Kd values of 210
and 213 nM, respectively, whereas mSPSB2 again
showed only low micromolar affinity (Kd=3.1 μM)
(Table 1). Overall, the relative affinities are consis-
tent with the higher sequence identity of mSPSB1
with SPSB4 (75%) compared to mSPSB2 (55%). The
additional five N-terminal residues in hPar-4(59–77)
make no significant contribution to the binding
affinity for mSPSB2 or mSPSB4.
Mutation to Ala of the conserved residues Tyr120
and Val206 in the loop regions of mSPSB2 (Supple-
lementary Fig. S1) reduced the binding affinity for
hPar-4(59–77) to the point where it could not be
quantified by ITC. Similarly, the triple mutants
[L123A,L124A,G125A] and [S126A,N127A,S128A]
showed no binding to hPar-4(59–77) according to
ITC (Table 1). The effect of mutation of Thr198 was
tested to explore the extent of the hPar-4 binding
surface (Fig. S1); the [T198A] mutant still bound
hPar-4(59–77), exhibiting a Kd of 3.0 μM.
Mutation of Asn72 in hPar-4(59–77) abolished
binding to mSPSB2 and mSPSB4 (Table 1). This
concurs with a previous study that demonstrated
poor binding of [N72A]hPar-4(67–81) to hSPSB1-
elonginBC10 and confirms that Asn72 is one of the
key residues mediating interactions with the SPSBFig. 2. Identification of key interacting residues of mSPSB2
labeled mSPSB2(12–224), free (red) and in a 1:1 complex with h
2H2O, pH 6.7, 295 K, at 500 MHz. The red peaks are labeled w
using the one-letter code and sequence positions (black). Conse
are important for GUSTAVUS/VASA10 and mSPSB2/hPar-4
arising from Arg side chains of mSPSB2 are shown in red (fre
different spectra widths used in the 15N dimension. (b) Weight
free and bound forms of 15N-labeled mSPSB2(12–224). Cyan
GUSTAVUS, mSPSB1, mSPSB2, and mSPSB4 and have been
except for mSPSB2 E55, where L66 is found in GUSTAVUS
residues that are known to be involved in mSPSB2/hPar-4 in
show cutoffs for weighted average chemical shift differences o
NH; the backbone amide resonance for this residue is close toproteins. Mutations of Asn70 and Asn71 to Ala in
the shorter hPar-4 peptide hPar-4(64–77) also abol-
ished binding to mSPSB1, mSPSB2, and mSPSB4
according to ITC (Table 1). For the double mutant
[E68D,L69I]hPar-4(64–77) (which provides hPar-4
with a DINNN motif similar to VASA), the binding
affinities for mSPSB1 and mSPSB4 increased by 5- to
6-fold, while the affinity for mSPSB2 increased by
30-fold (Table 1). Subsequently, we mutated each of
the two residues of the double mutant [E68D,L69I]
hPar-4(64–77) to establish which residues were im-
portant for the interactions. The affinities of [E68D]
hPar-4(64–77) and [L69I]hPar-4(64–77) to mSPSB2 in-
creased by 15- and 2-fold, respectively, compared to
wild type. In contrast, only small differences were
observed in the binding affinities of [E68D]hPar-
4(64–77) and [L69I]hPar-4(64–77) for mSPSB4 compared
with the double mutant (Table 1). Mutation N-
terminal to the predicted interface did not affect
binding, with [A66D]hPar-4(59–77) having wild-type
affinities for mSPSB2 and mSPSB4.
Structure of hPar-4(59–77)
hPar-4(59–77) is largely unstructured in aqueous
solution, consistent with predictions and experi-
mental data for the full-length protein.22 This is
evident from the 1H–15N heteronuclear single
quantum coherence (HSQC) spectrum that shows
limited peak dispersion in the 1H dimension (Fig.
S2). More than half the residues of hPar-4(59–77)
showed minimal deviations from random-coil
amide 1H shifts,23 the exceptions being the N- and
C-terminal residues Thr60, Ala62, Gly75, Gly76, and
Ala77 (Fig. S3a). Similarly, only the N- and C-
terminal residues, as well as Asn67 and Leu73,
showed chemical shift differences from random coil
in the 15N dimension (Fig. S3b).24
Identification of key interacting residues of
hPar-4(59–77) and mSPSB2
NMR interaction studies were performed by
saturating 104 μM 15N-hPar-4(59–77) with 380 μM
mSPSB2, resulting in 97% of 15N-hPar-4(59–77) being
bound to mSPSB2(12–224). Peaks for Asn70-Asn72 of
15N-hPar-4(59–77) could not be identified unambigu-
ously after saturation with mSPSB2(12–224) as these
resonances shifted significantly from their positions
in free hPar-4; peaks at 1H/15N chemical shifts of. (a) Comparison of HSQC spectra of 0.1 mM uniformly N-
Par-4(59–77) (blue). Spectra were recorded in 95% H2O/5%
ith sequence-specific assignments for free mSPSB2(12–224)
rved residues of GUSTAVUS and three SPSB proteins that
5 interactions are represented in cyan. Aliased resonances
e) and blue (complex) square boxes as these were due to
ed average chemical shift variations of 15N and 1H between
asterisks represent those residues that are conserved in
shown to be involved in GUSTAVUS binding to VASA,10
, mSPSB1, and mSPSB4. Orange asterisks indicate those
teraction according to a previous study.5 Horizontal lines
f 0.02 and 0.04 ppm. The Trp207 peak is from the indole
the water resonance5,21 and difficult to follow.
Table 2. ITC analysis of peptide interactions with hSPSB proteins
Protein:Peptide Kd
a (nM)
N (stoichiometric
ratio)
ΔHbinding
(kcal/mol)
TΔSbinding
(kcal/mol)
hSPSB1:hPar-4b 150±12 0.94 −13.2±0.1 −4.1±0.1
hSPSB1:VASAc 40±5 0.96 −20.5±0.2 −10.6±0.2
hSPSB2:hPar-4 1520±50 1.18 −16.2±0.1 −8.4±0.1
hSPSB2:VASA 147±7 0.96 −23.9±0.1 −14.7±0.1
hSPSB4:hPar-4 65±4 1.19 −17.0±0.1 −7.4±0.1
hSPSB4:VASA 4.0±0.7 0.97 −25.2±0.1 −13.9±0.1
a Deviations represent the errors of the curve fit to the data obtained using the single binding site model used within the Origin
software provided with the instrument.
b hPar-4(67–81) has sequence NELNNNLPGGAPAAP.
c VASA(184–203) has sequence DINNNNNIVEDVERKREFYI.
394 Structural Basis for Par-4 Recognition by SPSBs7.84 ppm/120.0 ppm and 8.06 ppm/114.5 ppm are
likely candidates for these resonances in the bound
form. Peaks corresponding to Ala62, Ala66, Asn67,
Leu69, Leu73, Gly75–76, and Ala77 were perturbed
(Fig. 1a), indicating that they are either involved
directly in the interaction or affected indirectly by
binding. The weighted averages of perturbations in
15N and 1H chemical shifts (Δδav) upon binding are
plotted in Fig. 1b.
Unlabeled hPar-4(59–77) was then added to 96 μM
15N-mSPSB2(12–224) to a final concentration of
227 μM, resulting in 99% of 15N-mSPSB2(12–224)
being bound to hPar-4(59–77). HSQC spectra of free
15N-mSPSB2(12–224) (red) and
15N-mSPSB2(12–224)
with hPar-4(59–77) bound (blue), including the side
chains of Gln116 and Trp207, are superimposed in
Fig. 2a. Aliased resonances arising from Arg side
chains of mSPSB2 are shown in red (free) and blue
(complex) square boxes. There were approximately
22 residues with weighted average chemical shift
variations N0.04 ppm and a further 7 with
N0.02 ppm (Fig. 2b). Peaks from conserved residues
of GUSTAVUS and three SPSB proteins that were
recognized to be important for GUSTAVUS/
VASA10 and mSPSB2/hPar-4 interactions5 are
labeled in cyan in Fig. 2a. The five residues involved
in GUSTAVUS binding to VASA are denoted by
cyan asterisks in Fig. 2b and the six involved in theTable 3. Data collection and refinement statistics
Protein hSPSB1/hPar-4 (I) hS
Data collection
PDB ID 2JK9
Space group P21
Cell dimensions
a, b, c (Å) 37.52, 82.96, 38.54 7
α, β, γ (°) 90.0, 104.42, 90.0
Resolution (Å) 1.79 (1.89–1.79)
Unique observations 20,682 (2853)
Completeness (%) 96.2 (91.4)
Redundancy 3.5 (3.3)
Rmerge 0.066 (0.536)
I/σI 12.7 (2.0)
Refinement
Resolution (Å) 1.79
Rwork/Rfree (%) 19.2/23.9
Number of atoms (protein/other/water) 1671/0/121
B-factors (Å2) (protein/other/water) 24.75/—/24.62
Values in parentheses correspond to the highest-resolution shell.mSPSB2/hPar-4 interaction are denoted by orange
asterisks. Key interacting residues are mapped onto
the mSPSB2 structure in Fig. S4.
Crystal structures of hSPSB1, SPSB2,
and SPSB4
To characterize the binding interface of SPSB
proteins in more detail, we performed extensive
crystallographic studies using the SPRY domains of
hSPSB1–4 together with the cognate substrate
peptide from hPar-4(67–81) and the VASA(184–203)
peptide from Drosophila. ITC studies on these
human proteins not only confirmed the weaker
binding to hPar-4 of hSPSB2 relative to hSPSB1 and
hSPSB4 but also revealed the far tighter binding of
all three proteins to the VASA-derived peptide
(Table 2). For example, the hSPSB2 affinity for
VASA is 10-fold greater (Kd=147 nM) than that for
hPar-4. High-resolution structures were solved for
hSPSB1 in complexes with hPar-4 and VASA, as
well as the hSPSB2/VASA complex and the apo-
hSPSB4 protein (see Table 3 for data collection and
refinement statistics; see Fig. S5 for electron density
maps). All three hSPSB proteins share the same
conserved SPRY domain fold with two short N-
terminal helices packed against a bent β-sandwich,
comprising two 7-stranded β-sheets (Fig. 3). The N-PSB1/VASA (II) hSPSB2/VASA (III) hSPSB4 (IV)
3F2O 3EMW 2V24
P212121 P212121 P3221
5.67, 80.65, 86.86 34.47, 61.96, 118.58 104.22, 104.22, 40.78
90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 120.0
2.05 (2.16–2.05) 1.80 (1.90–1.80) 2.20 (2.30–2.20)
34,014 (4899) 24,366 (3494) 13,208 (1635)
99.9 (100.0) 99.9 (100.0) 99.9 (100.0)
3.6 (3.5) 3.5 (3.5) 10.9 (10.9)
0.092 (0.649) 0.078 (0.618) 0.070 (0.560)
10.0 (2.0) 15.0 (3.1) 18.7 (3.4)
2.05 1.80 2.20
18.0/23.2 17.8/21.6 20.9/26.0
3490/0/287 1583/16/138 1533/1/78
32.79/—/31.26 28.98/41.44/37.63 38.23/21.06/34.57
Fig. 3. Crystal structures of hSPSB1, SPSB2, and SPSB4. (a) Overview of the structures of hSPSB1 in complex with
hPar-4 and VASA, as well as the hSPSB2 complex with VASA and apo-hSPSB4. Peptide ligands are shown as sticks. (b)
Molecular surface representation of hSPSB structures. The electrostatic surface potential is conserved across the hPar-4
binding site, but more varied beyond this epitope. (c) Sequence alignment of SPRY domain structures in the SPSB family.
Secondary-structure elements are shown for hSPSB1, including binding loops A–E. Key hPar-4 contact residues are
indicated by asterisks. Red and yellow shading indicate positions with sequence identity and sequence similarity,
respectively. An enhanced 3D visualization file displaying all structures is available for download (file S6).
395Structural Basis for Par-4 Recognition by SPSBsand C-terminal parts of the domain pack together
and, by similarity with GUSTAVUS [Protein Data
Bank (PDB) ID: 2FNJ], are expected to support the C-
terminal SOCS box. The opposite side of the β-
sandwich supports five extended loops (designated
A–E) that form the previously identified interaction
site for VASA (PDB ID: 2IHS).10Comparison of VASA binding to hSPSB1
and GUSTAVUS
The structure of hSPSB1 in complex with VASA
was refined to 2.05 Å resolution and contained two
copies of the protein complex in the asymmetric
unit. Overall, hSPSB1 residues 30–233 and VASA
396 Structural Basis for Par-4 Recognition by SPSBsresidues 184–201 were well defined. The two
hSPSB1 molecules superimpose with a main-chain
r.m.s.d. of 0.38 Å, with deviations observed in only
the N-terminus and the long loop connecting
β10–β11 (both distant from the peptide binding
site). Superimposition of GUSTAVUS (2IHS) and
hSPSB1 shows similar sites of divergence, with a
main-chain r.m.s.d. of 1.08 Å, reducing to 0.45 Å
upon exclusion of these same regions. The VASA
peptide is bound to GUSTAVUS and hSPSB1 in the
same extended manner, with the central loop B of
the protein dissecting the peptide into N- and C-
terminal interaction sites. Between these sites, the
central VASA residues Ile191, Val192, and Glu193
make little or no contact with the protein. The C-
terminal peptide residues were poorly defined in the
density, with only Asp194 and Glu196 forming
significant interactions with hSPSB1 Asn64 and
Leu63, respectively. This explains previous ITC
studies10 showing that the VASA binding affinity
is retained by a six-residue peptide (184–189,
DINNNN) derived from the N-terminal interaction
site. The VASA contact residues in hSPSB1 and
GUSTAVUS are conserved across both sites,
highlighting the importance of this interface, and
both complexes formed with similar affinity
(Kd ∼40 nM). Consequently, we limit further de-
scription of the VASA interface to its comparison
with hPar-4.
Conserved binding mode of hPar-4
The structure of hSPSB1 bound to hPar-4(67–81)
was refined to 1.79 Å resolution, enabling direct
comparison of the hPar-4 and VASA binding modes
in hSPSB1 (Fig. 4a). Residues Asn67-Pro74 from
hPar-4 were well defined, corresponding to the
minimal binding motif determined by NMR chem-
ical shift changes. Further electron density was not
present to build the C-terminal residues (75–81,
GGAPAAP), suggesting that, as for VASA, the N-
terminal site is sufficient for high-affinity interac-
tion. The hPar-4 and VASA peptides adopt similar
conformations, with tight superimposition of the
conserved NNN motifs, which form a total of six
conserved hydrogen bonds, including two between
hPar-4 Asn70 and hSPSB1 Thr111 (side and main
chain), one between Asn71 and the Gly218 carbonyl,
and three from Asn72 to Arg77, Tyr129, and the
Val216 carbonyl (Fig. 4b). One further conserved
main chain–main chain hydrogen bond is formed
between Asn70 of hPar-4 and the Gly218 amide of
hSPSB1. Notably, this position is deeply buried by
the close packing on either side of Tyr129 and
Trp217 from hSPSB1 loops D and E, respectively.
The main-chain conformation of hPar-4 deviates
from that of VASA on both sides of the NNN motif.
Towards the N-terminus, the Glu68 carboxyl moiety
of hPar-4 overlays well with VASA Asp184 to
hydrogen bond with hSPSB1 Tyr129 (equivalent to
SPSB2 Tyr120) and the three main-chain amides of
the NNN motif. This position is stabilized in VASA
by a 2. 6-Å intramolecular hydrogen bond formedbetween the amide of Asp184 and the main-chain
carbonyl of Asn188. However, the longer Glu68 side
chain of hPar-4 reorients the backbone to replace this
bond with the somewhat unfavorable 3.3-Å juxta-
position of the Glu68 β-carbon with the hPar-4
Asn72 carbonyl (Fig. 4c). At the N-terminus, the
hPar-4 residue Asn67 makes no contact with
hSPSB1. To the C-terminus of the NNN motif, the
introduction of a proline residue (Pro74) also
induces a main-chain shift; in VASA, the preceding
residue, Asn189, makes both main-chain amide and
carbonyl hydrogen bonds to the hSPSB1 backbone,
but in hPar-4, only the amide bond can form.
Neither Leu73 nor Pro74 in hPar-4 makes a
significant contribution to binding.
Comparison of hSPSB1 and hSPSB2
The hPar-4 binding residues in hSPSB1 are
completely conserved in hSPSB2 and yet the binding
of hSPSB2 to hPar-4 is weak (Kd=1.5 μM). Perhaps
as a result, we were able to crystallize hSPSB2 in
complex with the higher-affinity VASA peptide but
not the hPar-4 peptide. Nonetheless, this provides a
valuable structure for comparison with the hSPSB1–
peptide structures (Fig. 5). The weaker binding of
hSPSB2 has been noted previously and was pre-
dicted to result from amino acid changes in β7 and
loop D, where 116-QTDH-119 replace hSPSB1
residues 125-HSVG-128.10 In particular, the substi-
tution of hSPSB1 Gly128 was expected to distort the
neighboring tyrosine, which in hSPSB1 (Tyr129)
forms critical hydrogen bonds with Glu68 and
Asn72 in hPar-4, as well as hydrophobic contacts.
Indeed, mutation of these four positions to HSVG
improved the hSPSB2 affinity for hPar-4, albeit by
only fourfold.10
The most significant difference in the hSPSB2/
VASA structure is the complete lack of electron
density for the C-terminal residues of the peptide:
only residues Asp184-Asn190 are defined, com-
pared to Asp184-Phe201 in the equivalent hSPSB1
structure. Overlay of the two structures reveals a
likely clash between VASA Glu196 and hSPSB2
residues Glu55 and Gln116 (Fig. 5b). The N-
terminal region of the peptide is otherwise bound
through identical interactions, with conservation of
all interface positions. The amino acid substitutions
from Gln116-His119 do induce a subtle conforma-
tional change in β7 and loop D. For example, the φ
angle of hSPSB1 Gly128 changes from +72° to
−164° for the equivalent hSPSB2 residue His119.
However, changes to the neighboring hSPSB2
Tyr120 are minimal, with the lengths and angles
of its hydrogen bonds to VASA Asp184 and Asn188
being essentially unchanged (Fig. 5c). It appears
that further conformational changes are accommo-
dated by local readjustment across the entire
peptide binding site. Indeed, hSPSB2–peptide inter-
actions are associated with a higher entropic penalty
than those of hSPSB1 and hSPSB4 (Table 2).
Interestingly, the hSPSB2-bound VASA peptide
overlays closely with the hPar-4 backbone at its
Fig. 4. Comparison of the VASA and hPar-4 binding modes to hSPSB1. (a) Overlay of the hSPSB1 structures in
complex with VASA (dark green) and hPar-4 (light green). The surface of hSPSB1 is colored by electrostatic surface
potential. The peptide NNN motifs bind a shallow pocket centered on hSPSB1 Arg77. The peptide backbone deviates at
hPar-4 Glu68 where the shorter Asp184 side chain of VASA enables an intramolecular main-chain hydrogen bond with
VASA Asn188. (b) Stick representation showing the side-chain hydrogen bonds formed by the central hPar-4 NNNmotif.
Similar bonds are formed in the VASA complex. (c) Intramolecular hydrogen bonding in hPar-4 and VASA. The VASA
conformation is stabilized by an additional main-chain hydrogen bond between Asp184 and Asn188.
397Structural Basis for Par-4 Recognition by SPSBsvisible C-terminus and similarly can make only one
main-chain hydrogen bond from Asn189 as the
carbonyl and neighboring Asn190 are shifted away
from the protein surface. As expected, structural
conservation with hSPSB1 is greatest at the peptide
NNN motif and the loop D tryptophan that
supports it (Trp217 in hSPSB1 and Trp207 in
hSPSB2). This site appears unchanged by the
neighboring substitution of hSPSB1 His219 with
hSPSB2 Gln209.Structural changes upon ligand binding
Comparison of the apo-mSPSB2 structure (PDB ID:
3EK914) and the hSPSB2/VASA complex reveals only
modest loop rearrangements upon binding (Fig. 6a).
Moieties forming hydrogen bonds with the peptide
and those involved in hydrophobic interactions
reorient slightly to optimize those interactions. An
exception is the side-chain indole of hSPSB2 Trp207,
which is significantly rotated upon peptide binding to
Fig. 5. Comparison of the hSPSB1 and hSPSB2 binding
modes. Overlay of the hSPSB1 (orange) and hSPSB2
(green) structures in complex with VASA. (a) The N-
terminal region of VASA in both structures superimposes
well, but the C-terminal region was disordered in the
hSPSB2 structure. The hSPSB2 SPRY domain is shown in
green ribbon. (b) Overlay of the two structures reveals a
likely steric clash between the VASA C-terminal region
(orange) and the side chains of hSPSB2 Glu55 and Gln116
(green). (c) hSPSB1 and hSPSB2 show structural changes
in β7/loop D where hSPSB1 residues 125-HSVG-128 are
replaced by hSPSB2 116-QTDH-119. At a neighboring
position, only a small change is observed in the position of
the hSPSB2 Tyr120 hydrogen bond with VASA Glu196,
with little change in the overall bond length or geometry.
398 Structural Basis for Par-4 Recognition by SPSBspack against the side chain of VASA Asn187. The
identical conformation of this Trp in all hSPSB1,
hSPSB2, andGUSTAVUSpeptide complexes suggeststhat a rearrangement of this side chain is essential for
binding, in particular to alleviate a steric clash that
would otherwise arise from the apo conformation.
The apo-structures of mSPSB2 and hSPSB4 show
some additional differences in loop conformation (Fig.
6b). The most significant change affects loop B, where
hSPSB4 Pro79 and Val80 are displaced relative to the
corresponding residues in mSPSB2. However, the
orientation of the adjacent hSPSB4 Arg77 residue,
which would bind the third Asn (hPar-4 Asn72), is
essentially unchanged because of its largely buried
position in the β3 strand. Loops C (e.g., hSPSB4
Thr111) and E (e.g., hSPSB4 Trp217) are also some-
what displaced relative to mSPSB2, although their
overall conformations are similar. Again, a significant
rearrangement of the Trp side chain would be
required to accommodate the peptide ligand.
The lack of significant structural change upon
peptide binding is intriguing in light of previously
published NMR relaxation data and coarse-grained
dynamics simulations of mSPSB2,25 which found
evidence for flexibility in some loops of the protein
on the picosecond-to-nanosecond timescale (al-
though not on submillisecond-to-millisecond time-
scales). Perhaps these higher-frequency motions
were already dampened significantly in the crystal
structure of apo-mSPSB2.Discussion
The human proteins SPSB1–4 are expected to form
a subfamily of cullin5 E3 ligases comprising a SPRY
domain andC-terminal SOCS box. To date, substrate
recognition sites for the SPRY domain are identified
only for hPar-4 (ELNNNL) and the Drosophila
orthologue GUSTAVUS binding to a peptide from
VASA (DINNNN). The sequences of these peptides
suggest that further SPSB substrates may be identi-
fied from the consensus motif (E/D)(L/I)NNN. To
further investigate this consensus, we have deter-
mined the first structures of the human proteins
SPSB1, SPSB2, and SPSB4 as well as their binding
modes and affinities for both hPar-4 and VASA.
The structures show remarkable conservation of
the SPRY domain fold and absolute sequence
conservation for positions in contact with the (E/
D)(L/I)NNNmotif. For such a limited core motif, the
low nanomolar binding affinities of SPSB1 and
SPSPB4 are extraordinary, reflecting the highly
satisfied hydrogen bonding and complementary
packing interactions. Despite the sequence conserva-
tion, the majority of hydrogen bonds from the SPRY
domain originate from the main chain. In fact, the
contribution to the binding efficiency from side
chain–side chain hydrogen bonds is largely restricted
to Arg77 (loop B) and Tyr129 (loop D), although the
packing interactions are critically dependent on
Trp217 and Gly218 (hSPSB1 numbering). Notably,
all four residues are absent in hSPSB3, explaining its
lack of binding to hPar-4. The structural variation in
the loops of other SPRY domain families also
suggests that their specificities will differ.
Fig. 6. Structural changes upon ligand binding. (a) Overlay of the hSPSB2/VASA complex and apo-mSPSB2
structure.14 Side-chain rearrangements between the ligand-free and ligand-bound state are largely limited to hSPSB2
Trp207. The hSPSB2-bound VASA peptide is shown in ribbon representation for reference and colored orange. (b)
Overlay of the ligand-free structures of hSPSB4 andmSPSB2 reveals more substantial structural changes in loops B, C, and
E. The side chain of hSPSB4 Trp217 also shows a substantial rotamer change from mSPSB2 Trp207. Note that this residue
has an unusual backbone amide chemical shift in apo-mSPSB2.5
399Structural Basis for Par-4 Recognition by SPSBsGiven the restricted recognition motif and apparent
conservation of structure and interactions, two key
observations remain in question. Firstly, why is Asp
preferred over Glu at the start of the motif, and
secondly, why is the binding affinity of SPSB2 far
inferior to those of SPSB1 and SPSB4? The preference
for Asp at the first position is evident both from the
greater affinity ofVASAcompared tohPar-4 and from
the similar affinity increase provided by the direct
substitution of this residue into the lower affinity
hPar-4 peptide. Comparable hSPSB1 structures in
complex with VASA and hPar-4 reveal identical
positions of the Asp and Glu carboxyl, but the shorter
Asp side chain affords an additional intramolecular
main-chain hydrogen bond. This further stabilizes the
bound conformation of the peptide and provides a
rationale for the more favorable Asp interaction.
The effect of the Glu-to-Asp change is significantly
greater for SPSB2 than for SPSB4. This highlights the
hSPSB2 Tyr120 interaction with the Glu/Asp side
chain as a potential cause for its weak binding. The
substitution of hSPSB1 Gly128 to His119 in hSPSB2
flips the geometry of the backbone carboxyl for the
preceding residue, Asp118, producing a subtle
change in the hSPSB2 loop position. This is reflected
in an apparent shift of the Tyr120 position in a
structural overlay of the VASA complexes with
hSPSB1 and hSPSB2 (Fig. 5c). Indeed, substitutions
within β7/loop D have been shown previously to
increase hSPSB2 affinity for hPar-4 by fourfold.10 In
the structure of the hSPSB2/VASA complex, these
changes also prevent interaction of the VASA C-
terminal segment, and a main-chain hydrogen bond
is lost from SPSB2 Ala72 to the fourth Asn repeat
residue Asn189.Substitution of these hSPSB2 β7/loop D residues
with those of hSPSB1 does not provide a complete
rescue of hPar-4 affinity.10 Structural overlay of the
hSPSB1 and hSPSB2 complexes guided solely by the
VASA DINNN motif shows identical positioning of
both theDINNNpeptide residues and their hydrogen
bond partners in the SPRY domain. Therefore, assign-
ing affinity changes to individual positions (such as
hSPSB2 His119) in these structures may be too
simplistic, as conformational changes are dissipated
across the structure, reflecting the lower sequence
conservation of SPSB2 relative to SPSB1 and SPSB4
and their potentially different functions.20,26
The structures and affinity data presented here
provide the first structural description of the hSPSB
family and show the potential variation in their
substrate binding modes. The findings also provide
an extensive data set to challenge computational
algorithms that describe protein–protein interfaces.
Finally, the high affinities suggest that the (E/D)
(L/I)NNN consensus provides a good basis to
experimentally screen for additional SPSB family
substrates, and thus achieve a greater understand-
ing of their physiological function(s).Materials and Methods
Expression and purification
Full-length mSPSB1 (SWISS-PROT accession number
Q9D5L7) was cloned into a pGEX-4T vector (GE
Healthcare UK Ltd., Buckinghamshire, UK) that contained
human elonginB (SWISS-PROT accession number Q15370).
Similarly, mSPSB2 and mSPSB4 (SWISS-PROT accession
400 Structural Basis for Par-4 Recognition by SPSBsnumbers O88838 and Q8R5B6, respectively) were individ-
ually cloned into a pGEX-4T vector that contained murine
elonginB (SWISS-PROT accession number P62869). An N-
terminally truncated murine elonginC(17–112) starting at the
Met17 (SWISS-PROT accession number P83940)was cloned
into pBB75 vector for co-expression with mSPSB and
elonginB. Full-length SPSB proteins and elonginB were co-
expressed with elonginC in BL21(DE3) cells (Novagen, San
Diego, CA) at 30 °C for 4 h with 0.2 mM IPTG at OD600
(optical density at 600 nm)=0.6–0.8. The glutathione S-
transferase (GST)–SPSB–elonginBC complex was purified
using glutathione-Sepharose 4B (GE Healthcare, UK) and
cleaved from the GST-tag with one unit of thrombin (Roche
Applied Science, Germany) per 10 mg of fusion protein at
4 °C for 18 h on a rotating mixer. Flow-throughs of the
cleaved reactions were collected and purified further using
gel-filtration chromatography, Superdex 200 10/300 GL
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The
fractions of SPSB–elonginBC complex from gel-filtration
chromatographywere concentrated using a 3000molecular
weight cutoff centrifugal filter device, Amicon Ultra-4
(Millipore, Billerica, MA).
Shorter mSPSB constructs were also used for mSPSB1
and mSPSB4 lacking the C-terminal SOCS box region
(mSPSB1ΔSB and mSPSB4ΔSB); they were cloned into
pGEX-2T (GE Healthcare, UK). The shorter mSPSB2
construct excluded the first 11 residues at the N-terminus
and the C-terminus SOCS box [mSPSB2(12–224)].
mSPSB2(12–224) and mutants used in this study have been
described previously.21 Each of the mSPSBΔSB constructs
was expressed in Origami B(DE3) pLysS cells (Novagen,
Madison,WI) as a GST fusion protein at 20 °C for 24 hwith
0.5 mM IPTG added at OD600=0.6–0.8. The mSPSBΔSB
proteins were isolated according to the method used for
purifying the mSPSB–elonginBC complex.
Human SPSB constructs lacking the SOCS box region
[hSPSB1(24–233), SWISS-PROT accession number Q96BD6;
hSPSB2(26–219), Q99619 and hSPSB4(28–233), Q96A44] were
cloned into pNIC28-Bsa4 by ligation-independent cloning.
Constructs were transformed into BL21(DE3)-R3-pRARE2
and expressed overnight at 18 °C with 0.5 mM IPTG added
at OD600=0.5–0.8. hSPSB proteins were purified using Ni-
Sepharose (GE Healthcare, UK), eluted by imidazole and
subsequently cleaved from theN-terminal hexahistidine tag
by addition of tobacco etch virus protease (althoughhSPSB2
was resistant to cleavage). Further purification was
achieved by size-exclusion chromatography and finally
anion-exchange chromatography in the case of hSPSB1.
The cloning, expression, and purification of hPar-4(59–77)
and mutants are described in the Supplementary Data.
Synthetic hPar-4 and mutants
The shorter wild-type peptide hPar-4(64–77) and the
mutant peptides [N70A]hPar-4(64–77), [N71A]hPar-4(64–77),
and [E68D,L69I]hPar-4(64–77)were synthesizedbyGenScript
Corporation (Piscataway, NJ). The [A66D]hPar-4(59–77)
peptide was synthesized by GL Biochem (Shanghai,
China). For crystallization and ITC of hSPSB proteins, the
wild-type peptides hPar-4(67–81) and VASA(184–203) were
synthesized by ThermoElectron GmbH (Ulm, Germany).
NMR spectroscopy
All NMR experiments were performed on a Bruker
Avance500 spectrometer (Bruker BioSpin GmbH, Rhein-
stetten, Germany) using a TXI cryoprobe at 22 °C. All
NMR samples were prepared in 95% H2O/5%
2H2Ocontaining 10 mM sodium phosphate, 50 mM sodium
chloride, 2 mM ethylenediaminetetraacetic acid, and
0.02% (w/v) sodium azide at pH 6.7, to a final
concentration of approximately 0.1 mM, unless otherwise
indicated. Three-dimensional 15N-edited nuclear Over-
hauser enhancement spectroscopy (mixing time 250 ms),
15N-edited total correlated spectroscopy (spin lock time,
75 ms), and 15N HSQC spectra were recorded on uni-
formly labeled 15N-hPar-4(59–77) and
15N-mSPSB2(12–224).
The 1H chemical shifts were referenced indirectly to TMS
at 0 ppm via the H2O signal, while the
15N chemical shifts
were referenced indirectly using the 15N/1H γ-ratios.27
Spectra were processed using TOPSPIN version 1.3
(Bruker) and analyzed with XEASY version 1.3.28
Isothermal titration calorimetry
ITC measurements on mSPSB proteins were performed
at 22 °C using a MicroCalorimetry System (MicroCal,
Northhampton, MA). mSPSB1, mSPSB2, and mSPSB4
were prepared by dialyzing against 20 mM Tris, 150 mM
sodium chloride, and 2.5 mM calcium chloride at pH 8.0.
Measurements on hSPSB proteins were performed at 20 °C
using a VP-ITC titration calorimeter (MicroCal). hSPSB1
protein was dialyzed against 50 mM Hepes, pH 7.4,
150 mM NaCl, and 1 mM DTT. hSPSB2 and hSPSB4
proteins were dialyzed against 50 mM Hepes, pH 7.4,
150 mM NaCl, and 0.5 mM TCEP. Peptides for each
experiment were dissolved in the corresponding dialysis
buffers. ITC measurements were routinely carried out by
titrating 100 μM peptide solution into 10 μM protein.
Dilution enthalpies were determined separately by titrat-
ing peptide into buffer and used to correct the enthalpies
of the binding of protein and peptide. Data were analyzed
using a single binding site model implemented in the
Origin software package provided with the instrument.
Crystallization, data collection, and structure solution
hSPSB1 was buffered in 20 mM Hepes, pH 7.5, 100 mM
NaCl, 10 mM L-arginine, 10 mM L-glutamate, and 10 mM
DTT. hSPSB2 was buffered in 20 mM Hepes, pH 7.4,
150 mM NaCl, and 10 mM DTT. hSPSB4 was buffered in
50 mM Hepes, pH 7.5, 150 mM NaCl, and 5 mM DTT.
Peptides were added to a final concentration of 2 mM.
Crystallization was carried out using the sitting drop
vapor diffusion method at 4 °C. The complex of hSPSB1/
hPar-4 (I) was grown by mixing 75 nl of concentrated
protein (4 mg/ml) with 75 nl of a well solution containing
0.2 M Li2SO4, 0.1 M 2-[bis(2-hydroxyethyl)amino]-2-
(hydroxymethyl)propane-1,3-diol, pH 5.5, and 20% poly-
ethylene glycol (PEG) 3350. The complex of hSPSB1/
VASA (II) was grown by mixing 666 nl of the concentrated
protein (4mg/ml) with 333 nl of a well solution containing
0.2MNaCl, 0.1 M 2-[bis(2-hydroxyethyl)amino]-2-(hydro-
xymethyl)propane-1,3-diol, pH 5.5, and 25% PEG 3350.
The complex of hSPSB2/VASA (III) was grown by mixing
666 nl of the concentrated protein (9 mg/ml) with 333 nl of
a well solution containing 0.22 M Na/KPO4, 11% ethylene
glycol, and 22%PEG 3350. Apo-hSPSB4 (IV)was grown by
mixing 100 nl of protein with 50 nl of a solution containing
14.4% PEG 10 K, 0.16 M Ca(ac)2, 20% glycerol, and 0.08 M
cacodylate, pH 6.5. In all cases, crystals grew to diffracting
quality within a few days and were cryo-protected using
the well solution supplemented with 25% additional
ethylene glycol and were flash frozen in liquid nitrogen.
Data were collected at a Rigaku FRE Superbright
equipped with an RAXIS IV detector at 1.5 Å (I), or at the
401Structural Basis for Par-4 Recognition by SPSBsSwiss Light Source beamline PX10 in the case of (II) (at
1.00001 Å) and (IV) (at 0.9537 Å), or at the Diamond
Synchrotron beamline I03 in the case of (III) (at 0.9756 Å).
Indexing and integration was carried out usingMOSFLM29
and scaling was performed with SCALA30 for (I), (II), and
(III) or XDS31,32 and SHELX33 for (IV). Initial phases for (I)
and (IV) were calculated by molecular replacement with
PHASER34 using 2FNJ as a startingmodel. Initial phases for
(II) were calculated likewise using an ensemble comprising
2FNJ, 2V24, and 2IHS starting models. The models were
completed manually in Coot35 and were refined with
REFMAC5.34 The final model of (I) was used to obtain
phases for (III) followed by manual build in Coot35 and
refinement with REFMAC5.34 In all cases, thermal motions
were analyzed using TLSMD36 and hydrogen atoms were
included in late refinement cycles. Data collection and
refinement statistics can be found in Table 3.
Accession numbers
The models and structure factors have been deposited
with PDB accession codes: 2JK9 (I), 3F2O (II), 3EMW (III),
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